Michael Derby

Founder and Chief Executive Offer at Castle Creek Pharmaceuticals, LLC

Michael is the Founder and CEO of Castle Creek Pharmaceuticals, which he has built from a complete startup to one of the fastest growing specialty pharmaceutical companies in the industry. Castle Creek has rapidly assembled a robust portfolio of products backed by strong science and focused on meeting patient needs in the treatment of rare and debilitating dermatologic and head and neck conditions.

Mr. Derby is a successful entrepreneur, operating executive and investor, with 20 years of experience in the pharmaceutical industry and broader life sciences sector. He has founded or co-founded four specialty pharmaceutical companies, and has a passion for developing and commercializing innovative drugs for patients with rare diseases and other serious medical conditions.

Prior to starting Castle Creek, Mr. Derby founded Norphan Pharmaceuticals, a specialty pharmaceutical company focused on the development of drugs for orphan neurologic disease, which he ran in its early stages and sold to Marathon Pharmaceuticals in a successful financing-turned-acquisition transaction in 2013. Mr. Derby joined Marathon to oversee the transition of the Norphan assets, and also led Marathon’s business development effort through 2015. One of the Norphan products has become the first drug to gain unconditional approval in the U.S. for the treatment of Duchenne Muscular Dystrophy.

From 2008 to 2011, Mr. Derby served as a lead Healthcare Partner at the early-stage private equity and investment advisory firm, Centerstone Partners. At Centerstone, he led or co-led the formation, fundraising, corporate strategy development and early management of a number of companies spanning the pharmaceutical, clinical research and diagnostics industries, including the spinout of Omnicare Clinical Research (renamed Theorem Clinical Research) from Omnicare, Inc. in an acquisition by a major private equity firm. In 2015, Theorem Clinical Research was sold to Chiltern in a highly successful exit event. Prior to Centerstone, Mr. Derby was a venture capitalist with EGS Healthcare Capital Partners, and also previously worked in key commercial roles for Merck & Co. and Forest Laboratories.

Mr. Derby holds advanced degrees in business and science, with an M.B.A., with distinction, from New York University’s Stern School of Business, an M.S. in Neuroscience from the University of Rochester, and a B.S., with honors, from Johns Hopkins University, where he was a Beneficial Hodson merit scholar and member of the Tau Beta Pi engineering honor society.

Alle sessies door Michael Derby

Educational Panel

ma, 12 feb 2018 4 p.m. - 4:55 p.m.
Salon 4